ClinicalTrials.gg
CompletedNCT00792103NP101-008Updated Feb 4, 2016Results posted

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

A Phase 3 interventional study of NP101 in Migraine Disorders, sponsored by NuPathe Inc.. Completed at 34 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-02-04.

Sponsored by NuPathe Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
198
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. — none open to participants now, none under way, none of them phase 3. Migraine Disorders · Teva Pharmaceutical Industries, Ltd..

Enrollment
15th of 19
198 · median 353
Started
2009
with 3 others
Phase 3
12 of 20
none open now
Registered
6th of 20
by date

Among the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd., this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2009, is one of 12 in phase 3, and was the 6th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

None of the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. is open now. The open studies under Migraine Disorders, anywhere →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. as a file.
02

Study summary

The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by:

  • Subject self-examination skin irritation scores
  • Adverse events
  • Changes in vital signs and ECG parameters

The secondary objective is to evaluate the long term efficacy of NP101 as assessed by:

  • Headache pain free at two hours after patch activation for all initial acute migraine attacks treated with NP101
  • Headache pain relief at two hours after patch activation for all initial acute migraine attacks treated with NP101
  • Nausea free at two hours after patch activation for all initial acute migraine attacks treated with NP101
  • Phonophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101
  • Photophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101
  • Migraine free at two hours after patch activation for all initial acute migraine attacks treated with NP101

This study will use an open-label design to assess the long term safety of NP101 (sumatriptan iontophoretic transdermal patch).

Subjects who continue to be in good health (use of a triptan or use of an NP101 patch is not contraindicated) and received treatment (patch activation) with the study patch for a qualifying migraine under study NP101-007 will be considered eligible for enrollment into the open-label study. Subjects will be expected to remain in the study for up to 12 months.

03

Conditions studied

  • Migraine Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject was previously enrolled in study NP101-007 and treated (patch activation) a qualifying migraine.
  • Subject will be judged to be in good health, based upon the results of a medical history, physical examination, vital signs, and . Subjects will not have any abnormal vital signs or ECG parameters in order to qualify for enrollment. ECG must be done at enrollment for NP101-008 unless ECG for the Final Visit of study NP101-007 was conducted within 30 days.
  • Female subjects of (not surgically sterile or 2 years post menopausal) must have a negative pregnancy test at enrollment.

Exclusion criteria

Exclusion Criteria:

  • Subject has less than two potential skin application sites.
  • Subject has abnormal vital signs or parameters or had an adverse event while participating in NP101-007 that would preclude the continued treatment with the NP101 patch.
  • Subject has had changes in their medical history or medication use that would preclude their use of sumatriptan as per the approved Imitrex® product Prescribing Information (PI) or their safe use of NP101 as per the NP101 Investigator's Brochure.
  • Subject has or plans to start, stop, change treatment or dose of any of the following within 3 months prior to the subject's study Enrollment date and through the Final Visit: anxiolytics, lithium and other mood stabilizers such as valproate, carbamazepine or lamotrigine, hypnotics or antipsychotics.
  • Subject has taken non-triptan serotonergic drugs including selective serotonin reuptake inhibitor (SSRI), serotonin and norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressants (TCAs), monoamine oxidase inhibitor (MAOI) or preparations containing St. John's Wort within 1 month prior to enrollment and/or is planning to start any of these medications during the study (through Final Visit).
  • Female subjects who are pregnant, breast feeding, or of , and are not using or are unwilling to use an effective form of during the study and for a period of 30 days following Final Visit. Acceptable methods of contraception include barrier method with spermicide, intrauterine device (IUD), steroidal contraceptive (oral, transdermal, implanted or injected) or abstinence. If the exclusive male partner is surgically sterile, this will be acceptable.
  • Subject has participated in a clinical study within 30 days of enrollment (excluding NP101-007) or is planning to participate in another clinical study for the duration of NP101-008.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    NP101

    sumatriptan iontophoretic transdermal patch

    Drug: NP101

Interventions

06

What researchers measure

Primary outcomes

  1. Subject Self-examination of Skin Irritation

    For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin).

    Time frame: 24 hours post patch activation

Secondary outcomes

  1. Pain Relief

    Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101.

    Time frame: 2 hours

  2. Nausea Free

    Nausea free at two hours after patch activation.

    Time frame: 2 hours

  3. Phonophobia Free

    Phonophobia free at two hours after patch activation.

    Time frame: 2 hours

  4. Photophobia Free

    Photophobia free at two hours after patch activation.

    Time frame: 2 hours

07

Results

Posted May 7, 2013

Participant flow

The study was initiated January 2009 and completed in September 2010. Patients were enrolled from 34 investigative sites across the United States.

Participant flow — Overall Study
MilestoneNP101
Started198
Completed65
Not completed133
Withdrew: Enrolled, not treated15
Withdrew: Lost to follow-up17
Withdrew: Adverse event25
Withdrew: Withdrawal by subject52
Withdrew: Protocol violation10
Withdrew: Did not apply 6 patches in 1st 3 mths14

Outcome measures

SecondaryPain Relief

Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101.

Time frame:
2 hours
Reported as:
Number · participants
Pain Relief
participantsNP101
Pain Relief105 ± 0.341
PrimarySubject Self-examination of Skin Irritation

For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin).

Time frame:
24 hours post patch activation
Reported as:
Mean · scores on a scale
Subject Self-examination of Skin Irritation
scores on a scaleNP101
Subject Self-examination of Skin Irritation1.0 ± 0.96
SecondaryNausea Free

Nausea free at two hours after patch activation.

Time frame:
2 hours
Reported as:
Number · participants
Nausea Free
participantsNP101
Nausea Free143
SecondaryPhonophobia Free

Phonophobia free at two hours after patch activation.

Time frame:
2 hours
Reported as:
Number · participants
Phonophobia Free
participantsNP101
Phonophobia Free109
SecondaryPhotophobia Free

Photophobia free at two hours after patch activation.

Time frame:
2 hours
Reported as:
Number · participant
Photophobia Free
participantNP101
Photophobia Free97

Adverse events

Collected over All adverse events were collected from study enrollment until 30 days after the last patch application.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NP101—2/183 (1.1%)66/183 (36.1%)
Most frequent serious events
Most frequent serious events
EventNP101
VertigoEar and labyrinth disorders1/183
DehydrationMetabolism and nutrition disorders1/183
Most frequent other events
Most frequent other events
EventNP101
Application site pruritusGeneral disorders40/183
Application Site PainGeneral disorders39/183
Application site hypersensitivityGeneral disorders11/183

Baseline characteristics

Per protocol, the intent-to-treat (ITT) population was defined as all subjects who applied and activated at least one NP101 study patch and had at least one post baseline assessment for each migraine symptom (pain, photophobia, phonophobia, and nausea). Of the 183 subjects who applied at least one study patch, 181 subjects met the ITT criteria.

Age, Categorical
Age, Categorical(Participants)NP101
<=18 years0
Between 18 and 65 years183
>=65 years0
Age, Continuous
Age, Continuous(years)NP101
Mean42.0 ± 10.28
Sex: Female, Male
Sex: Female, Male(Participants)NP101
Female152
Male31
Region of Enrollment
Region of Enrollment(participants)NP101
United States183
08

Study locations

34 sites
  • Phoenix, Arizona, United States
  • Little Rock, Arkansas, United States
  • Newport Beach, California, United States
  • San Francisco, California, United States
  • Santa Monica, California, United States
  • Fairfield, Connecticut, United States
  • Ocala, Florida, United States
  • Palm Beach Gardens, Florida, United States
  • Sunrise, Florida, United States
  • Atlanta, Georgia, United States
  • Columbus, Georgia, United States
  • Decatur, Georgia, United States
  • Savannah, Georgia, United States
  • Chicago, Illinois, United States
  • Ann Arbor, Michigan, United States
  • Kalamazoo, Michigan, United States
  • Springfield, Missouri, United States
  • St. Louis, Missouri, United States
  • Mount Vernon, New York, United States
  • Plainview, New York, United States
  • Greensboro, North Carolina, United States
  • West Chester, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Wynnewood, Pennsylvania, United States
  • Memphis, Tennessee, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Alexandria, Virginia, United States
  • Virginia Beach, Virginia, United States
  • Seattle, Washington, United States
09

References and documents

Publications

  • Smith TR, Goldstein J, Singer R, Pugach N, Silberstein S, Pierce MW. Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache. 2012 Apr;52(4):612-24. doi: 10.1111/j.1526-4610.2012.02094.x. Epub 2012 Feb 21. PubMed 22352764 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 2 years 8 months after primary completion. A results delay was requested in Nov 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2008
First posted
Nov 17, 2008
Start
Jan 2009
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results delay requested
Nov 7, 2012
Results first posted
May 7, 2013
Last update
Feb 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00792103
Lead sponsor
NuPathe Inc.
Responsible party
Sponsor
First posted
Nov 17, 2008
Start date
Jan 2009
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
May 7, 2013
Last update
Feb 4, 2016

Study contacts

Mark Pierce, MD PhD
study chair · NuPathe Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nigella sativa oil · Black Seed Oil Extract Supplement · Sumatriptan

Start the discussion